S1PR1 and multiple sclerosis: In March 2020, ozanimod capsules, agonists for S1PR1 and S1PR5, were approved for application in the treatment of relapsing forms of multiple sclerosis by the US FDA, involving clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.